Risk Factors for Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Women Treated with ZidovudineLynne Mofenson, George J. Nemo, John S. Lambert et al.|New England Journal of Medicine|1999Cited by 553
Efficacy of Zidovudine and Human Immunodeficiency Virus (HIV) Hyperimmune Immunoglobulin for Reducing Perinatal HIV Transmission from HIV‐Infected Women with Advanced Disease: Results of Pediatric AIDS Clinical Trials Group Protocol 185E. Richard Stiehm, Hunter Hammill, John S. Lambert et al.|The Journal of Infectious Diseases|1999Cited by 149
The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 EnvelopeMark de Souza, Silvia Ratto‐Kim, Weerawan Chuenarom et al.|The Journal of Immunology|2012Cited by 140
Safety and Pharmacokinetics of Hyperimmune Anti-Human Immunodeficiency Virus (HIV) Immunoglobulin Administered to HIV-Infected Pregnant Women and Their NewbornsJohn S. Lambert, Alice Stek, Lynne Mofenson et al.|The Journal of Infectious Diseases|1997Cited by 63
Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn InfantsColeen K. Cunningham, Karin Nielsen‐Saines, Elizabeth J. McFarland et al.|The Journal of Infectious Diseases|2019Cited by 62